FDA — authorised 17 April 2020
- Application: NDA213411
- Marketing authorisation holder: SEAGEN
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Tukysa in United States
FDA authorised Tukysa on 17 April 2020
Marketing authorisation
Tukysa in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United States
Frequently asked questions
Is Tukysa approved in United States?
Yes. FDA authorised it on 17 April 2020.
Who is the marketing authorisation holder for Tukysa in United States?
SEAGEN holds the US marketing authorisation.